Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Baksh, Sheriza, Wen, Jiajun, Mansour, Omar, Chang, Hsien-Yen, McAdams-DeMarco, Mara, Segal, Jodi B., Ehrhardt, Stephan, Alexander, G. Caleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371013/
https://www.ncbi.nlm.nih.gov/pubmed/34404825
http://dx.doi.org/10.1038/s41598-021-95687-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371013/
https://www.ncbi.nlm.nih.gov/pubmed/34404825
http://dx.doi.org/10.1038/s41598-021-95687-z

Ejemplares similares